Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Antiproliferative treatment of patients with metastatic endocrine gastroenteropancreatic tumours (GEP) is based mainly on chemotherapeutic protocols whereby drug toxicity is a major handicap. Octreotide is the first choice in the control of hormone mediated symptoms. From retrospective and a few pro...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Arnold, R, Trautmann, M E, Creutzfeldt, W, Benning, R, Benning, M, Neuhaus, C, Jürgensen, R, Stein, K, Schäfer, H, Bruns, C, Dennler, H J
Materialtyp: Artigo
Språk:Inglês
Publicerad: 1996
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC1383075/
https://ncbi.nlm.nih.gov/pubmed/8675099
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk